LAPATINIB STADA 250mg film-coated tablets medication leaflet

L01EH01 • lapatinib • Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors

Lapatinib is a medication used to treat advanced or metastatic breast cancer, particularly in cases where tumors overexpress the HER2 receptor. It is a tyrosine kinase inhibitor that blocks cellular signaling involved in cancer cell growth and survival.

The medication is taken orally, usually once daily, and is used in combination with other therapies such as capecitabine or letrozole. Treatment is carried out under the supervision of an oncologist.

Side effects may include diarrhea, nausea, skin rash, fatigue, or loss of appetite. In rare cases, severe adverse effects such as liver or cardiac toxicity may occur.

Patients should inform their doctor about any other medications they are taking and strictly follow the administration instructions. Pregnant or breastfeeding women should not use this medication.